Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completed

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

NCT04298463
completed

Xydalba Utilization Registry in France

NCT03726216
terminated

Xydalba Utilization Registry in Germany

NCT03696901

Clinical Trials (3)

Showing 3 of 3 trials
NCT04298463

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

Completed
NCT03726216

Xydalba Utilization Registry in France

Completed
NCT03696901

Xydalba Utilization Registry in Germany

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3